| Autor: |
Bond A; Eli Lilly & Co., Ltd., Lilly Research Centre, Erl Wood Manor, Surrey, UK., Ragumoorthy N, Monn JA, Hicks CA, Ward MA, Lodge D, O'Neill MJ |
| Jazyk: |
angličtina |
| Zdroj: |
Neuroscience letters [Neurosci Lett] 1999 Oct 08; Vol. 273 (3), pp. 191-4. |
| DOI: |
10.1016/s0304-3940(99)00663-1 |
| Abstrakt: |
The neuroprotective effects of a selective Group II metabotropic glutamate receptor (mGluR) agonist, LY379268, have been evaluated against global and focal cerebral ischaemia. Loss of CA1 hippocampal neurones following 5 min bilateral occlusion of the carotid artery (BCAO) in the gerbil was almost completely prevented by LY379268 (10 mg/kg, i.p.) given 30 min post-occlusion (P < 0.001); 10 mg/kg 1 h after and 20 mg/kg 2 h after BCAO also produced significant neuroprotection (P < 0.05). Similarly the BCAO-induced increase in TUNEL positive cells at 5 days post-occlusion was reduced by LY379268. By contrast the size of the infarct following middle cerebral artery occlusion (MCAO) induced by endothelin-1 infusion in the rat was unaffected by either 10 or 20 mg/kg i.p. of LY379268. This contrast between the results from these two animal models with LY379268, agrees with previous data on a less potent but similarly selective mGluR2/3 agonist, LY354740. It further suggests that mGluR Group II agonists are likely to have more utility in global, than in focal, cerebral ischaemia. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect